Cottage Street Advisors LLC decreased its holdings in Illumina, Inc. (NASDAQ:ILMN) by 1.5% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 16,350 shares of the life sciences company’s stock after selling 250 shares during the period. Illumina comprises approximately 2.1% of Cottage Street Advisors LLC’s investment portfolio, making the stock its 17th biggest holding. Cottage Street Advisors LLC’s holdings in Illumina were worth $3,572,000 as of its most recent SEC filing.

Other large investors have also modified their holdings of the company. Federated Investors Inc. PA increased its position in shares of Illumina by 46.2% during the second quarter. Federated Investors Inc. PA now owns 3,704 shares of the life sciences company’s stock worth $642,000 after purchasing an additional 1,171 shares in the last quarter. Neuberger Berman Group LLC increased its position in shares of Illumina by 35.7% during the second quarter. Neuberger Berman Group LLC now owns 4,893 shares of the life sciences company’s stock worth $849,000 after purchasing an additional 1,286 shares in the last quarter. Los Angeles Capital Management & Equity Research Inc. acquired a new position in shares of Illumina during the second quarter worth $226,000. Eaton Vance Management increased its position in shares of Illumina by 0.5% during the second quarter. Eaton Vance Management now owns 15,927 shares of the life sciences company’s stock worth $2,764,000 after purchasing an additional 84 shares in the last quarter. Finally, Northwestern Mutual Wealth Management Co. increased its position in shares of Illumina by 116.5% during the second quarter. Northwestern Mutual Wealth Management Co. now owns 1,520 shares of the life sciences company’s stock worth $264,000 after purchasing an additional 818 shares in the last quarter. 91.60% of the stock is owned by institutional investors.

In related news, Director Jay T. Flatley sold 20,000 shares of the company’s stock in a transaction dated Tuesday, October 24th. The shares were sold at an average price of $210.43, for a total transaction of $4,208,600.00. Following the completion of the transaction, the director now owns 539,176 shares in the company, valued at approximately $113,458,805.68. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, SVP Charles Dadswell sold 145 shares of the company’s stock in a transaction dated Wednesday, January 3rd. The stock was sold at an average price of $224.50, for a total transaction of $32,552.50. Following the transaction, the senior vice president now owns 7,411 shares of the company’s stock, valued at approximately $1,663,769.50. The disclosure for this sale can be found here. Over the last three months, insiders have sold 137,671 shares of company stock worth $29,485,768. Corporate insiders own 0.89% of the company’s stock.

Illumina, Inc. (NASDAQ ILMN) traded up $4.68 during mid-day trading on Tuesday, hitting $244.72. 975,700 shares of the stock traded hands, compared to its average volume of 1,170,022. The company has a debt-to-equity ratio of 0.41, a quick ratio of 3.73 and a current ratio of 4.22. Illumina, Inc. has a twelve month low of $156.50 and a twelve month high of $245.96. The stock has a market cap of $36,090.00, a price-to-earnings ratio of 46.17, a P/E/G ratio of 3.30 and a beta of 0.79.

Illumina (NASDAQ:ILMN) last posted its earnings results on Tuesday, October 24th. The life sciences company reported $1.11 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.99 by $0.12. Illumina had a net margin of 30.34% and a return on equity of 19.42%. The business had revenue of $714.00 million for the quarter, compared to analyst estimates of $692.77 million. During the same period in the prior year, the company posted $0.97 EPS. The company’s revenue for the quarter was up 17.6% on a year-over-year basis. research analysts expect that Illumina, Inc. will post 3.76 EPS for the current year.

ILMN has been the topic of several research reports. Deutsche Bank set a $275.00 target price on Illumina and gave the company a “buy” rating in a research report on Tuesday. BTIG Research initiated coverage on Illumina in a research report on Friday, January 5th. They issued a “neutral” rating on the stock. BidaskClub raised Illumina from a “hold” rating to a “buy” rating in a research report on Friday, January 5th. William Blair downgraded Illumina from an “outperform” rating to a “market perform” rating in a research report on Friday, January 5th. Finally, Evercore ISI initiated coverage on Illumina in a research report on Wednesday, January 3rd. They issued an “outperform” rating and a $250.00 target price on the stock. One equities research analyst has rated the stock with a sell rating, nine have issued a hold rating and fourteen have issued a buy rating to the company’s stock. Illumina presently has an average rating of “Buy” and an average price target of $220.13.

ILLEGAL ACTIVITY NOTICE: This report was first published by Watch List News and is the property of of Watch List News. If you are accessing this report on another domain, it was illegally copied and republished in violation of US and international trademark & copyright legislation. The correct version of this report can be viewed at https://www.watchlistnews.com/cottage-street-advisors-llc-sells-250-shares-of-illumina-inc-ilmn/1809168.html.

About Illumina

Illumina, Inc (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations.

Want to see what other hedge funds are holding ILMN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Illumina, Inc. (NASDAQ:ILMN).

Institutional Ownership by Quarter for Illumina (NASDAQ:ILMN)

Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with Analyst Ratings Network's FREE daily email newsletter.